Arndt Vogel, Professor at the University of Toronto and Longo Family Chair in Liver Cancer Research at University Health Network, shared on X:
“Off the press!Pre-Liver Transplant Immunotherapy and Post-Transplant Outcomes in HCC: Global LIFT-HCC-1 Study
- 408 patients.
- Tumor burden and AFP at liver transplantation associated with HCC recurrence.
- Rejection associated with non-HBV etiology, immune-related adverse events (irAEs), age and shorter ICI washout.
Pre-transplant immune checkpoint inhibitor therapy appears feasible, but its clinical utility still needs to be established.

Other articles about Liver Cancer on OncoDaily.
You can also read: Hans Christian Andersen’s Cause of Death: His Final Journey With Liver Cancer
